{
    "title": "T-Cell Therapy",
    "inventor_name": "Steven A. Rosenberg",
    "publication_year": 2018,
    "device_name": "Adoptive Cell Transfer (ACT) using Tumor-Infiltrating Lymphocytes (TILs)",
    "goal": "Achieve complete regression of metastatic cancers, especially breast cancer, by targeting patient-specific tumor mutations.",
    "problem_addressed": "Metastatic breast cancer unresponsive to standard chemotherapy, hormonal therapy, and other treatments.",
    "concept_summary": "A personalized immunotherapy that sequences a patient's tumor to identify somatic mutations, isolates tumor-infiltrating lymphocytes (TILs) that recognize mutant proteins, expands those TILs ex vivo, and reinfuses them together with checkpoint-inhibitor antibodies and IL-2 to induce a durable anti-tumor immune response.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Adoptive cell transfer",
        "Mutation-specific T-cell targeting",
        "Checkpoint inhibition",
        "Cytokine support (IL-2)"
    ],
    "scientific_domains": [
        "Immunology",
        "Oncology",
        "Molecular Biology",
        "Genetics"
    ],
    "mechanisms_of_action": [
        "TILs recognize neo-antigens presented on MHC molecules",
        "PD-1/TIM-3 enrichment selects tumor-reactive T cells",
        "Checkpoint blockade prevents T-cell exhaustion",
        "IL-2 promotes T-cell proliferation after infusion"
    ],
    "materials": [
        "Peripheral blood mononuclear cells (PBMCs)",
        "Tumor-infiltrating lymphocytes (TILs)",
        "Cytokine IL-2",
        "Checkpoint inhibitor pembrolizumab (anti-PD-1 antibody)"
    ],
    "energy_sources": [],
    "inputs": [
        "Patient tumor tissue (DNA/RNA)",
        "Peripheral blood sample",
        "Sequencing data of tumor mutations",
        "Culture media and cytokines for T-cell expansion"
    ],
    "outputs": [
        "Expanded, mutation-specific TIL infusion product",
        "Clinical tumor regression"
    ],
    "claimed_performance": "Complete durable regression of metastatic breast cancer lasting >22 months after infusion of ~90 billion TILs; similar responses reported in other epithelial cancers.",
    "experimental_evidence": "Case report of a single metastatic breast-cancer patient (Nature Medicine, 2018) and ongoing Phase 2 clinical trial (NCT01174121) showing tumor shrinkage in multiple patients.",
    "replication_status": "Only a single-patient case report confirmed; larger Phase 2 trial ongoing but results not yet published.",
    "keywords": [
        "Adoptive cell transfer",
        "Tumor-infiltrating lymphocytes",
        "Neo-antigen",
        "Personalized immunotherapy",
        "Breast cancer",
        "Checkpoint inhibitor"
    ],
    "related_technologies": [
        "CAR-T cell therapy",
        "Cancer vaccines",
        "PD-1/PD-L1 blockade"
    ],
    "controversy_level": "low",
    "confidence_score": 0.9,
    "practicability_score": 0.6,
    "fringe_score": 0.2,
    "evidence_strength": 0.7,
    "risk_score": 0.3,
    "trl_estimate": 5,
    "source_urls": [
        "https://www.cancer.gov/news-events/press-releases/2018/immunotherapy-targets-breast-cancer-case-report",
        "https://www.bbc.com/news/health-44338276",
        "https://www.nature.com/articles/s41591-018-0040-8",
        "https://clinicaltrials.gov/ct2/show/NCT01174121",
        "http://rexresearch.com/rosenbergtcelltherapy/US2018148690A1.pdf",
        "http://rexresearch.com/rosenbergtcelltherapy/US2018133253A1.pdf"
    ],
    "organizations": [
        "National Cancer Institute (NCI)",
        "National Institutes of Health (NIH)"
    ],
    "applications": [
        "Treatment of metastatic breast cancer",
        "Personalized therapy for other mutation-bearing epithelial cancers"
    ],
    "limitations": [
        "Requires individualized tumor sequencing",
        "Complex, labor-intensive cell manufacturing",
        "Efficacy limited to patients whose tumors harbor immunogenic mutations",
        "Current evidence limited to small case series"
    ],
    "open_questions": [
        "Can the approach be scaled to larger patient populations?",
        "What is the long-term durability beyond 2 years?",
        "How does tumor heterogeneity affect TIL efficacy?",
        "Can combination with other immunotherapies improve response rates?"
    ],
    "red_flags": [],
    "evidence_quotes": [
        "All of this patient's cancer disappeared and has not returned more than 22 months later.",
        "The researchers sequenced DNA and RNA from one of her tumors... identified 62 different mutations in her tumor cells.",
        "TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient.",
        "A patient with metastatic breast cancer... was treated with tumor-infiltrating lymphocytes (TILs) reactive against mutant versions of four proteins... complete durable regression."
    ]
}